AstraZeneca’s (AZN) Airsupra U.S. prescribing information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. The BATURA Phase IIIb trial, which evaluated severe exacerbation risk reduction, examined the efficacy of as-needed Airsupra compared to as-needed albuterol, the most commonly used rescue medication for asthma in the U.S. The BATURA trial demonstrated treatment with Airsupra significantly reduced the risk of a severe exacerbation by 46% when compared with albuterol in adult patients with mild asthma.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Brit Pop: HSBC, AZN, ARM – 3 British Stocks Saluted By Our AI Analyst
- AstraZeneca reports Saphnelo demonstrates reduction in disease activity
- Mixed Trial Results Shape Outlook for AstraZeneca Stock
- Trump’s UK Visit Prompts GSK to Commit $30B in U.S. Investment
- Trump Weekly: Trump signs pharma order, FTC opens inquiry into AI chatbots